Publications

Beltran H, Yelensky R, Frampton GM, Park K, , MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM et al..  2013.  Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.. Eur Urol. 63(5):920-6.

Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H et al..  2014.  Aggressive variants of castration-resistant prostate cancer.. Clin Cancer Res. 20(11):2846-50.

Beltran H, Jendrisak A, Landers M, Mosquera JM, Kossai M, Louw J, Krupa R, Graf RP, Schreiber NA, Nanus DM et al..  2016.  The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.. Clin Cancer Res. 6(22)

Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopolou E, Chakravarthi BV, Varambally S et al..  2016.  Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.. Nat Med. 3(22):298-305.

Beltran H, Antonarakis ES, Morris MJ, Attard G.  2016.  Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.. Am Soc Clin Oncol Educ Book. (35):131-41.

Beltran H.  2014.  The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential.. Mol Cancer Res. 12(6):815-22.

Beltran H, Rubin MA.  2013.  New strategies in prostate cancer: translating genomics into the clinic.. Clin Cancer Res. 19(3):517-23.

Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, Rubin MA, Nanus DM.  2012.  Challenges in recognizing treatment-related neuroendocrine prostate cancer.. J Clin Oncol. 30(36):386-9.